{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:09:36Z","timestamp":1792177776500,"version":"4.4.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.yebeh.2019.05.014","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T18:44:37Z","timestamp":1560192277000},"page":"67-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A randomized, open-label, multicenter comparative trial of levetiracetam and topiramate as adjunctive treatment for patients with focal epilepsy in Korea"],"prefix":"10.1016","volume":"97","author":[{"given":"Sang Kun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Ahm","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Loesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pelgrims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Osakabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byungin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2019.05.014_bb0005","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.seizure.2007.02.011","article-title":"Efficacy and safety of levetiracetam as adjunctive treatment of refractory partial seizures in a multicentre open-label single-arm trial in Korean patients","volume":"16","author":"Heo","year":"2007","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2019.05.014_bb0010","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1684\/epd.2013.0599","article-title":"The long-term efficacy and safety of levetiracetam in a tertiary epilepsy entre","volume":"15","author":"Kang","year":"2013","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2019.05.014_bb0015","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1528-1157.1999.tb01596.x","article-title":"Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial. Korean Topiramate Study Group","volume":"40","author":"Korean Topiramate Study Group","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.05.014_bb0020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/seiz.2001.0605","article-title":"Low dose and slow titration of topiramate as adjunctive therapy in refractory partial epilepsies: a multicentre open clinical trial","volume":"11","author":"Korean Topiramate Study Group","year":"2002","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2019.05.014_bb0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.seizure.2007.05.019","article-title":"Long-term effects of levetiracetam and topiramate in clinical practice: a head-to-head comparison","volume":"17","author":"Bootsma","year":"2008","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2019.05.014_bb0030","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.seizure.2007.01.004","article-title":"Comparative retention rates and long-term tolerability of new antiepileptic drugs","volume":"16","author":"Chung","year":"2007","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2019.05.014_bb0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1600-0404.2008.01062.x","article-title":"Retention rates of new antiepileptic drugs in localization-related epilepsy: a single-center study","volume":"119","author":"Peltola","year":"2009","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2019.05.014_bb0040","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00415-017-8526-8","article-title":"Comparative effectiveness of eight antiepileptic drugs in adults with focal refractory epilepsy: the influence of age, gender, and the sequence in which drugs were introduced onto the market","volume":"264","author":"M\u00e4kinen","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2019.05.014_bb0045","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/WNF.0000000000000204","article-title":"Three-year retention rates of levetiracetam, topiramate, and oxcarbazepine: a retrospective hospital-based study","volume":"40","author":"Sunwoo","year":"2017","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2019.05.014_bb0050","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yebeh.2010.04.001","article-title":"Measuring outcomes of treatment with antiepileptic drugs in clinical trials","volume":"18","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.05.014_bb0055","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1111\/j.1528-1167.2009.02177.x","article-title":"Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: an observational study","volume":"50","author":"Cho","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.05.014_bb0060","author":"US Food and Drug Administration"},{"key":"10.1016\/j.yebeh.2019.05.014_bb0065","author":"US Food and Drug Administration"},{"key":"10.1016\/j.yebeh.2019.05.014_bb0070","author":"European Medicines Agency"},{"key":"10.1016\/j.yebeh.2019.05.014_bb0075","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1528-1157.2000.tb00165.x","article-title":"Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy","volume":"41","author":"Lhatoo","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.05.014_bb0080","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.seizure.2008.07.007","article-title":"Retention of new AEDs in institutionalized intellectually disabled patients with epilepsy","volume":"8","author":"Carpay","year":"2009","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2019.05.014_bb0085","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.yebeh.2006.12.005","article-title":"Long-term retention rates of new antiepileptic drugs in adults with chronic epilepsy and learning disability","volume":"10","author":"Simister","year":"2007","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.05.014_bb0090","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/archneurol.2010.49","article-title":"Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy","volume":"67","author":"Arif","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.yebeh.2019.05.014_bb0095","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3346\/jkms.2012.27.3.285","article-title":"Prevalence of treated epilepsy in Korea based on national health insurance data","volume":"27","author":"Lee","year":"2012","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.yebeh.2019.05.014_bb0100","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40272-015-0147-z","article-title":"Trends in antiepileptic drug prescriptions for childhood epilepsy at a tertiary children's hospital in Korea","volume":"17","author":"Cho","year":"2001","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.yebeh.2019.05.014_bb0105","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.seizure.2005.11.006","article-title":"Evidence for a rapid action of levetiracetam compared to topiramate in refractory partial epilepsy","volume":"15","author":"Specchio","year":"2006","journal-title":"Seizure"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019303877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019303877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:28:53Z","timestamp":1761503333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505019303877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":21,"alternative-id":["S1525505019303877"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.05.014","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized, open-label, multicenter comparative trial of levetiracetam and topiramate as adjunctive treatment for patients with focal epilepsy in Korea","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}